Revenue Forecast

The revenue estimate for the base year 2023 is 555.6 million, with a CAGR of 6.5% for the study period from 2023 to 2028.

The Impact of the Top 3 Strategic Imperatives on Europe’s NIPT Industry

Disruptive Technologies

Why: Disruptive technologies, such as single-cell analysis (SCNA), are changing traditional procedures in Europe’s NIPT industry, which can completely transform NIPT precision and dependability. Unlike conventional techniques that use maternal blood samples, SCNA analyzes individual fetal cell DNA. The accurate detection of hidden genetic abnormalities by SCNA’s precise cell analysis considerably improves NIPT accuracy despite challenges related to limited fetal DNA and maternal interference. By offering expectant parents comprehensive insights about fetal health, NIPT integration could establish new benchmarks.

Frost Perspective: SCNA will completely change the NIPT industry. Its personalized examination of fetal cell DNA will transform the precision of traditional techniques. Because SCNA detects small genetic abnormalities that traditional NIPT techniques miss, it will provide a better understanding and diagnosis of prenatal disorders. If SCNA sees wide adoption, it could redefine industry standards, offering more precise, comprehensive insight into fetal health. Illumina, Nature, and Thermo Fisher Scientific, leading innovators in genetic analysis, are exploring or adopting SCNA in their methodologies.

Competitive Intensity

Why: A dynamic and robust competitive landscape, with well-established major players such as Illumina, Natera, and Roche Diagnostics, defines the European NIPT industry. Innovators include start-ups, such as FreenoMe, ArcherDX, and Semora. FreenoMe uses artificial intelligence (AI)-powered genomic analysis for disease detection and prenatal testing. Using next-generation sequencing (NGS), ArcherDX specializes in accurate genetic testing to provide personalized medication. To establish new benchmarks in prenatal diagnostics, these players are driving innovations, such as SCNA.

Frost Perspective: The rapid innovation in the European NIPT industry, driven by start-ups and well-established firms, is profoundly transforming the basics of prenatal diagnostics. For example, the market’s dynamics and accessibility for expectant parents are changing. As the industry is competitive, new entrants face both opportunities and tensions. Innovative collaborations among firms will guide initial developments and marketing strategies, making targeted outreach essential for the NIPT industry’s long-term success.

Industry Convergence

Why: Industry convergence in the NIPT sector is a process with various industries, technologies, and services coming together to offer new opportunities. To improve prenatal diagnostics, AI in genetic testing increases accuracy by identifying subtle anomalies. Partnerships between genetic testing companies and healthcare providers streamline prenatal care by providing expectant parents with essential support during their pregnancy. Advanced sequencing, microfluidics, and bioinformatics improve fetal DNA profiling, providing more accurate and actionable information about fetal health, thus enhancing the overall prenatal diagnostic strategy for expectant parents.

Frost Perspective: The NIPT industry's convergence could revolutionize prenatal diagnostics, profoundly impacting the market. Collaborations between diagnostics, technology, and healthcare services create profound changes in prenatal care. This convergence generates significant advantages, enabling effective partnerships that enhance diversity and innovation. As an evolving market, companies in the NIPT space must collaborate to meet evolving parental care needs.

Scope of the Study

Content

• This research provides an overview of the NIPT industry across Europe.
• The study encompasses a 5-year industry revenue forecast from 2023 to 2028, focusing on the NIPT segment. The scope does not include prenatal genetic testing, such as carrier screening for cystic fibrosis, or invasive tests, such as amniocentesis, CVS, and miscarriage tests.
• The study focuses on NIPT to detect conditions such as trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), monosomy X (Turner syndrome), XXY Klinefelter syndrome, trisomy X (triple X syndrome), XYY Jacob syndrome, 22q11.2 deletion syndrome, 1p36 deletion syndrome, 15q11.2 deletion syndrome, 5p deletion (Cri du chat syndrome), and 4p deletion (Wolf-Hirschhorn syndrome).
• The forecast analysis for Europe’s NIPT industry corresponds to the breakdown by country.
• These forecasts use a qualitative approach for the growth opportunity analyses because of the industry’s private nature and lack of quantitative measures.

Scope

Competitive Environment

Key Competitors

• BGI Genomics

• Illumina

• Natera, Inc.
• Roche Diagnostics
• Eurofins LifeCodexx GmbH
• Yougen Health
• Biocartis
• Qiagen
• Labcorp
• Cradle Genomics
• Invitae
• Prematha Health
• PerkinElmer
• Sophia Genetics
• Quest Diagnostics
• Menarini
• Ariosa Diagnostics
• Berry Genomics
• Prenetics
• Blueprint Genetics
• Multiplicom
• Centogene
• NIPD Genetics
• OncoDNA
• Verinata Health
• Genomic Diagnostic
• Igexomix